
TatvaCare, a health care technology company specializing in digital therapeutics, is working to change the approach to asthma and COPD management. Its Digital Therapeutic (DTx) app, BREATHE-DTx will begin clinical trials in India.
The trials, led by pulmonologist Agam Vora, MD, in Mumbai, India, are particularly important in India, where over 30 million people have a chronic respiratory disorder, such as asthma or COPD. BREATHE-DTx combines personalized patient care plans, IoT device-led monitoring, coaching and counseling services to improve compliance and provide comprehensive and effective care for patients with chronic respiratory conditions.
The focus of the study is to assess the impact of BREATHE-DTx on reducing exacerbations and incidents, ultimately improving the quality of life for patients who have these chronic conditions. The study will leverage a diverse patient population, over a period of six months.
“At TatvaCare, we are looking for advanced technology and digital interventions to deliver exceptional health care solutions,” said TatvaCare CEO Manoj Balaji. “We believe that such advancements will improve the lives of patients with chronic disease conditions which often require long-term care that is consistent and delivered with precision. Under the guidance of Dr. Agam Vora and the team of pulmonologists, BREATHE-DTx is our first step to offering next-level of customer-centric care through scientific, evidence-backed research and collaboration.”
To test the efficacy, acceptability and ease of convenience, TatvaCare will begin BREATHE-DTx clinical trials to test the application at various centers across India. More than 150-200 participants will be randomly tested to gauge the user efficacy and advantages. Based on the outcomes of the trial, TatvaCare will launch this first-of-its-kind digital therapeutics solution in India for COPD and asthma management. The market for digital health applications in India is valued at $3.8 billion and estimated to jump to $18 billion by 2030.